Sensus Healthcare (NASDAQ:SRTS) Upgraded at Wall Street Zen

Sensus Healthcare (NASDAQ:SRTS) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

A number of other equities research analysts also recently issued reports on SRTS. Zacks Research upgraded Sensus Healthcare from a “strong sell” rating to a “hold” rating in a research report on Wednesday, October 22nd. Weiss Ratings reissued a “sell (d)” rating on shares of Sensus Healthcare in a research report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $8.00.

Sensus Healthcare Stock Down 0.3%

Sensus Healthcare stock opened at $3.83 on Friday. Sensus Healthcare has a 52-week low of $3.03 and a 52-week high of $9.08. The firm’s fifty day moving average is $3.75 and its 200 day moving average is $3.97. The company has a market cap of $62.89 million, a price-to-earnings ratio of -20.16 and a beta of 1.24.

Sensus Healthcare (NASDAQ:SRTS) last posted its earnings results on Thursday, November 6th. The company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.06. The firm had revenue of $6.88 million for the quarter, compared to the consensus estimate of $6.31 million. Sensus Healthcare had a negative net margin of 8.44% and a negative return on equity of 5.67%. On average, equities research analysts anticipate that Sensus Healthcare will post 0.32 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Joseph C. Sardano acquired 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 18th. The stock was bought at an average price of $4.03 per share, for a total transaction of $100,750.00. Following the acquisition, the chief executive officer directly owned 1,200,293 shares of the company’s stock, valued at $4,837,180.79. This represents a 2.13% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Eric Sachetta acquired 7,000 shares of the stock in a transaction on Friday, November 21st. The stock was bought at an average cost of $3.93 per share, with a total value of $27,510.00. Following the completion of the transaction, the director owned 140,113 shares in the company, valued at $550,644.09. This trade represents a 5.26% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased a total of 36,500 shares of company stock worth $147,570 in the last ninety days. 8.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Sensus Healthcare

Hedge funds have recently made changes to their positions in the company. Kingstone Capital Partners Texas LLC purchased a new position in Sensus Healthcare in the second quarter worth $3,170,000. Divisadero Street Capital Management LP lifted its holdings in shares of Sensus Healthcare by 459.4% during the 2nd quarter. Divisadero Street Capital Management LP now owns 324,673 shares of the company’s stock valued at $1,539,000 after purchasing an additional 266,635 shares during the last quarter. Acadian Asset Management LLC boosted its position in shares of Sensus Healthcare by 35.3% in the 1st quarter. Acadian Asset Management LLC now owns 470,713 shares of the company’s stock worth $2,225,000 after purchasing an additional 122,746 shares in the last quarter. Trexquant Investment LP purchased a new position in Sensus Healthcare during the 1st quarter worth $93,000. Finally, Evernest Financial Advisors LLC acquired a new position in Sensus Healthcare during the 2nd quarter valued at about $255,000. 25.30% of the stock is currently owned by hedge funds and other institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.